Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 3 (October)

1. SIFT: a method to verify the IMRT fluence delivered during patient treatment using an electronic portal imaging device.
   Int J Radiat Oncol Biol Phys, 60(3): 981-93. [Abstract] [Full-text]
2. Automated model-based organ delineation for radiotherapy planning in prostatic region.
   Int J Radiat Oncol Biol Phys, 60(3): 973-80. [Abstract] [Full-text]
3. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
   Int J Radiat Oncol Biol Phys, 60(3): 896-908. [Abstract] [Full-text]
4. Ultrasound probe pressure as a source of error in prostate localization for external beam radiotherapy.
   Int J Radiat Oncol Biol Phys, 60(3): 788-93. [Abstract] [Full-text]
5. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
   Int J Radiat Oncol Biol Phys, 60(3): 777-87. [Abstract] [Full-text]
6. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy.
   Int J Radiat Oncol Biol Phys, 60(3): 767-76. [Abstract] [Full-text]
7. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer.
   Biochem Biophys Res Commun, 324(1): 154-65. [Abstract] [Full-text]
8. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
   Mol Carcinog, 41(3): 150-63. [Abstract] [Full-text]
9. Identification of differentially methylated CpG islands in prostate cancer.
   Int J Cancer, 112(5): 840-5. [Abstract] [Full-text]
10. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate.
    Int J Cancer, 112(5): 787-92. [Abstract] [Full-text]
11. Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population.
    Int J Cancer, 112(5): 872-6. [Abstract] [Full-text]
12. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model.
    Int J Cancer, 112(5): 823-9. [Abstract] [Full-text]
13. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.
    Int J Biochem Cell Biol, 37(2): 442-50. [Abstract] [Full-text]
14. Vattikuti Institute prostatectomy, a technique of robotic radical prostatectomy for management of localized carcinoma of the prostate: experience of over 1100 cases.
    Urol Clin North Am, 31(4): 701-17. [Abstract] [Full-text]
15. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.
    Eur Urol, 46(5): 660-9; discussion 669. [Abstract] [Full-text]
16. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Eur Urol, 46(5): 571-8. [Abstract] [Full-text]
17. European collaborative group on prostate brachytherapy: preliminary report in 1175 patients.
    Eur Urol, 46(5): 565-70; discussion 570. [Abstract] [Full-text]
18. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
    Mutat Res, 555(1): 21-32. [Abstract] [Full-text]
19. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    J Bone Miner Res, 19(11): 1766-70. [Abstract] [Full-text]
20. Attitudes and beliefs concerning prostate cancer genetic screening.
    Clin Genet, 66(5): 445-51. [Abstract] [Full-text]
21. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
    Gene Ther, 11(21): 1559-67. [Abstract] [Full-text]
22. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion.
    Cancer Lett, 215(2): 239-47. [Abstract] [Full-text]
23. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Am J Epidemiol, 160(9): 825-41. [Abstract] [Full-text]
24. Investigation of extrinsic and intrinsic apoptosis pathways of new clerodane diterpenoids in human prostate cancer PC-3 cells.
    Eur J Pharmacol, 503(1): 17-24. [Abstract] [Full-text]
25. Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth.
    Int J Cancer, 112(6): 951-8. [Abstract] [Full-text]
26. Expression of proto-oncogene c-kit in high risk prostate cancer.
    Eur J Surg Oncol, 30(9): 987-92. [Abstract] [Full-text]
27. Boric acid inhibits human prostate cancer cell proliferation.
    Cancer Lett, 216(1): 21-9. [Abstract] [Full-text]
28. Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life.
    J Pain Symptom Manage, 28(5): 433-44. [Abstract] [Full-text]
29. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls.
    Cancer, 101(9): 2011-9. [Abstract] [Full-text]
30. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
    Cancer, 101(9): 2001-5. [Abstract] [Full-text]
31. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
    Mol Endocrinol, 18(11): 2633-48. [Abstract] [Full-text]
32. Papillary cystadenocarcinoma of the prostate.
    Int J Urol, 11(11): 1036-8. [Abstract] [Full-text]
33. Early catheter removal 3 days after radical retropubic prostatectomy.
    Int J Urol, 11(11): 983-8. [Abstract] [Full-text]
34. Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci.
    Am J Hum Genet, 75(6): 948-65. [Abstract] [Full-text]
35. Apoptosis of circulating tumor cells in prostate cancer patients.
    Cytometry A, 62(1): 46-53. [Abstract] [Full-text]
36. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma.
    Prostate, 61(4): 324-31. [Abstract] [Full-text]
37. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells.
    Prostate, 61(4): 354-70. [Abstract] [Full-text]
38. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Prostate, 61(4): 332-53. [Abstract] [Full-text]
39. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
    Prostate, 61(4): 318-23. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.